1.98 USD
↘ 0.03 (1.25%)LIVE (AS OF 01:24 PM EDT)
Allogene Therapeutics, Inc. Common Stock
ALLONASDAQ • USD
Market: OPEN
Open?$2.03
High?$2.05
Low?$1.96
Prev. Close?$2.00
Volume?2.8M
Avg. Volume?13.7M
VWAP?$2.00
Rel. Volume?0.20x
Bid / Ask
Bid?$1.97 × 47.1K
Ask?$1.98 × 11.2K
Spread?$0.01
Midpoint?$1.98
Valuation & Ratios
Market Cap?690.0M
Shares Out?345.2M
Float?150.9M
Float %?67.1%
P/E Ratio?N/A
P/B Ratio?2.47
EPS?-$0.50
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Themes
Employees
152
Market Cap
690.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-10-11
Address
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?9.65Strong
Quick Ratio?9.65Strong
Cash Ratio?1.07Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score100/100
P/E?N/A▾
P/B?2.47CHEAP▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-3.8CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-62.3%WEAK▾
ROA?-43.9%WEAK▾
Cash Flow & Enterprise
FCF?$-109526000
Enterprise Value?$659.7M
Fundamentals ratios updated end of day